Top 10 Key Players in the South Korea Scleroderma Market | Competitive Landscape 2026

South Korea Scleroderma Market Overview

According to 6Wresearch, the South Korea scleroderma market is growing rapidly due to the rising prevalence of autoimmune disorders and the rising adoption of biological therapies. Scleroderma is recognized by the hardening of the skin and potential damage to internal organs such as the lungs and heart. The growing occurrence of Interstitial Lung Disease associated with scleroderma has led to an increasing demand for antifibrotic treatments. The increased investment in biotechnology and the development of biosimilars are further contributing to the growth of the market.

Competitive Landscape

The competitive landscape of the South Korea Scleroderma Industry includes global pharmaceutical giants and innovative domestic biotech firms, offering the latest technology-based therapeutic tools required for the management of the disease. The prominent leaders are actively engaged in the development and supply of immunosuppressants, antifibrotics, and vasodilators. These companies are focused on the development of innovative products required for the management of scleroderma-related complications.

Below is a list of leading players operating in the South Korea Scleroderma Market:

1. Boehringer Ingelheim Korea

Boehringer Ingelheim is a dominant leader with its flagship antifibrotic treatment, which is widely used for scleroderma-associated interstitial lung disease.

2. Roche Korea

Roche provides essential biological therapies, which has gained traction for treating the systemic manifestations of the disease.

3. Celltrion

Celltrion is a major player in the biosimilar space, offering high-quality, cost-effective alternatives to biological treatments used in managing autoimmune conditions.

4. Janssen Korea (Johnson & Johnson)

Janssen is a key player in providing pulmonary arterial hypertension treatments, often required by systemic sclerosis patients.

5. Novartis Korea

Novartis focuses on specialized immunosuppressants and targeted therapies designed to control the overactive immune response in scleroderma patients.

6. Pfizer Korea

Pfizer provides critical anti-inflammatory and immunosuppressive medications used extensively in various stages of scleroderma treatment.

7. Bayer Korea

Bayer is a leading player providing Adempas, a key treatment for pulmonary hypertension associated with connective tissue diseases.

8. GSK Korea (GlaxoSmithKline)

GSK is a prominent player, offering biological treatments and endothelin receptor antagonists for the management of vascular complications in scleroderma.

9. Enzychem Lifesciences

Enzychem is a prominent domestic biotech firm engaged in the research and development of novel compounds targeting inflammatory diseases.

10. AprilBio Co., Ltd.

AprilBio is an emerging player focused on long-acting fusion proteins and innovative antibodies for the treatment of various autoimmune conditions.